Cargando…

Chemotherapy use near the end-of-life in patients with metastatic breast cancer

INTRODUCTION: Very few data are available regarding the use of chemotherapy in patients with metastatic breast cancer (MBC) near the end-of-life, i.e., the final month. The aim of this study was to provide a descriptive analysis of its use in two different European geographic areas (Sweden and Greec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Edman Kessler, Luisa, Sigfridsson, Johnny, Hatzidaki, Dora, Bergh, Jonas, Foukakis, Theodoros, Georgoulias, Vasilios, Matikas, Alexios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220858/ https://www.ncbi.nlm.nih.gov/pubmed/32383058 http://dx.doi.org/10.1007/s10549-020-05663-w

Ejemplares similares

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2017)

Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer()
por: Matikas, Alexios, et al.
Publicado: (2017)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Detection of circulating tumour cells before and following adjuvant chemotherapy and long-term prognosis of early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2022)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
por: Vamvakas, Lambros, et al.
Publicado: (2014)

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Matikas, Alexios, et al.
Publicado: (2015)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Role of circulating free DNA in colorectal cancer
por: Matikas, Alexios, et al.
Publicado: (2016)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial
por: Mijwel, Sara, et al.
Publicado: (2018)

Variable expression levels of keratin and vimentin reveal differential EMT status of circulating tumor cells and correlation with clinical characteristics and outcome of patients with metastatic breast cancer
por: Polioudaki, Hara, et al.
Publicado: (2015)

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy
por: Kotsakis, A, et al.
Publicado: (2016)

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
por: Vriens, B. E. P. J., et al.
Publicado: (2017)

Average duration of prior treatment lines predicts clinical benefit to eribulin chemotherapy in patients with metastatic breast cancer
por: Coe, Faye, et al.
Publicado: (2021)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer
por: Agelaki, Sofia, et al.
Publicado: (2015)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer—results of an exploratory case–control study
por: Krajnak, S., et al.
Publicado: (2020)

Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
por: Cazzaniga, M. E., et al.
Publicado: (2021)

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
por: Thorén, Linda, et al.
Publicado: (2023)

Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients
por: Kallergi, Galatea, et al.
Publicado: (2015)

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
por: Hirbe, Angela C., et al.
Publicado: (2018)

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
por: Mavroudis, Dimitrios, et al.
Publicado: (2017)

Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer
por: Wilson, Florence R., et al.
Publicado: (2017)

Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
por: Rugo, Hope S., et al.
Publicado: (2020)

Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

In‐hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial
por: Müllhaupt, Gautier, et al.
Publicado: (2019)

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m535bqed6teeloin1om82ca889